BioAge Labs (NASDAQ:BIOA) Stock Rating Upgraded by Roth Mkm

BioAge Labs (NASDAQ:BIOA) was upgraded by Roth Mkm to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

A number of other equities analysts have also weighed in on BIOA. Piper Sandler began coverage on BioAge Labs in a research note on Tuesday, January 27th. They set an “overweight” rating for the company. Oppenheimer began coverage on BioAge Labs in a research report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 target price on the stock. Needham & Company LLC began coverage on BioAge Labs in a research report on Friday, March 27th. They set a “buy” rating and a $50.00 target price on the stock. Citigroup raised their target price on BioAge Labs from $15.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, March 10th. Finally, Morgan Stanley set a $23.00 target price on BioAge Labs in a research report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, BioAge Labs has a consensus rating of “Moderate Buy” and an average target price of $43.50.

BioAge Labs Price Performance

NASDAQ BIOA opened at $16.95 on Wednesday. The stock’s fifty day moving average price is $17.54 and its 200 day moving average price is $16.37. BioAge Labs has a 1 year low of $3.79 and a 1 year high of $24.00. The company has a market cap of $753.43 million, a price-to-earnings ratio of -7.06 and a beta of 0.99.

BioAge Labs (NASDAQ:BIOA) last released its earnings results on Friday, May 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.19. The firm had revenue of $2.77 million for the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. Research analysts expect that BioAge Labs will post -2.59 earnings per share for the current year.

Institutional Trading of BioAge Labs

A number of hedge funds and other institutional investors have recently made changes to their positions in BIOA. Janus Henderson Group PLC increased its holdings in shares of BioAge Labs by 411.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock worth $36,597,000 after buying an additional 1,685,063 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of BioAge Labs in the fourth quarter worth $13,892,000. Stempoint Capital LP acquired a new position in shares of BioAge Labs in the first quarter worth $5,923,000. Millennium Management LLC grew its stake in shares of BioAge Labs by 749.8% in the third quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock worth $1,803,000 after acquiring an additional 270,479 shares in the last quarter. Finally, Sphera Funds Management LTD. acquired a new position in shares of BioAge Labs in the fourth quarter worth $3,215,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.